ebselen has been researched along with Cerebral Ischemia in 22 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 9.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 5.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Pretreatment with ebselen prevented the death by 56% and attenuated neurological damage (abnormal eyelid drooping, hair bristling, muscle tone, flexor reflex, posture, and walking patterns)." | 5.40 | Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils. ( Daily, JW; Kang, S; Kim, DS; Moon, NR; Park, S; Shin, BK, 2014) |
| "Ebselen is a mimic of glutathione peroxidase that reacts with peroxynitrite and inhibits nitric oxide (NO) synthase." | 5.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "In ebselen-treated rats, the extent of tissue immunopositive for 8-oxodGuo, and 4-HNE was less than that demonstrating ischemic damage confirming the antioxidant mechanism of action in vivo." | 5.32 | Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. ( Graham, DI; Imai, H; Macrae, IM; Masayasu, H, 2003) |
| "Pretreatment with ebselen, which induced significant (P < 0." | 5.32 | Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. ( Alborch, E; Burguete, MC; Marín, N; Pérez-Asensio, FJ; Pitarch, C; Romero, FJ; Salom, JB; Torregrosa, G, 2004) |
| "Ebselen treatment resulted in a significant lowering of IL-6 plasma levels (26 +/- 5 pg/ml) as compared with that seen in lesioned vehicle controls (48 +/- 9 pg/ml) at 24 h postlesion." | 5.31 | Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. ( Arteel, GE; Bidmon, HJ; Divanach, A; Gladilin, S; Sies, H; Witte, OW; Zilles, K, 2000) |
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 5.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| " Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents." | 4.82 | Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005) |
| "LFB staining was used to detect demyelination." | 1.91 | Ebselen alleviates white matter lesions and improves cognitive deficits by attenuating oxidative stress via Keap1/Nrf2 pathway in chronic cerebral hypoperfusion mice. ( Cheng, B; Dong, F; Liu, Y; Meng, Q; Song, X; Yan, W; Yao, R, 2023) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 1.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Pretreatment with ebselen prevented the death by 56% and attenuated neurological damage (abnormal eyelid drooping, hair bristling, muscle tone, flexor reflex, posture, and walking patterns)." | 1.40 | Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils. ( Daily, JW; Kang, S; Kim, DS; Moon, NR; Park, S; Shin, BK, 2014) |
| "Ebselen is a mimic of glutathione peroxidase that reacts with peroxynitrite and inhibits nitric oxide (NO) synthase." | 1.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "In ebselen-treated rats, the extent of tissue immunopositive for 8-oxodGuo, and 4-HNE was less than that demonstrating ischemic damage confirming the antioxidant mechanism of action in vivo." | 1.32 | Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. ( Graham, DI; Imai, H; Macrae, IM; Masayasu, H, 2003) |
| "Pretreatment with ebselen, which induced significant (P < 0." | 1.32 | Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. ( Alborch, E; Burguete, MC; Marín, N; Pérez-Asensio, FJ; Pitarch, C; Romero, FJ; Salom, JB; Torregrosa, G, 2004) |
| "Ebselen treatment resulted in a significant lowering of IL-6 plasma levels (26 +/- 5 pg/ml) as compared with that seen in lesioned vehicle controls (48 +/- 9 pg/ml) at 24 h postlesion." | 1.31 | Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. ( Arteel, GE; Bidmon, HJ; Divanach, A; Gladilin, S; Sies, H; Witte, OW; Zilles, K, 2000) |
| "Ebselen (EBS) is a seleno-organic compound with glutathione peroxidase-like activity which is neuroprotective in acute stroke ischemia." | 1.31 | Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat. ( Mello, CF; Rocha, JB; Rossato, JI; Rubin, MA; Zeni, G, 2002) |
| "3." | 1.30 | Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. ( Graham, DI; Macrae, IM; Masayasu, H; Peters, EE; Takasago, T, 1997) |
| "Pretreatment with ebselen (10 or 30 mg/kg p." | 1.29 | The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. ( Dawson, DA; Graham, DI; Macrae, IM; Masayasu, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KM | 1 |
| Kim, KH | 1 |
| Kang, TC | 1 |
| Kim, WY | 1 |
| Lee, Mr | 1 |
| Jung, HJ | 1 |
| Hwang, IK | 2 |
| Ko, SB | 1 |
| Koh, JY | 1 |
| Won, MH | 2 |
| Oh, Eg | 1 |
| Shin, I | 1 |
| Dong, F | 1 |
| Yan, W | 1 |
| Meng, Q | 1 |
| Song, X | 1 |
| Cheng, B | 1 |
| Liu, Y | 1 |
| Yao, R | 1 |
| Aras, M | 1 |
| Altaş, M | 1 |
| Meydan, S | 1 |
| Nacar, E | 1 |
| Karcıoğlu, M | 1 |
| Ulutaş, KT | 1 |
| Serarslan, Y | 1 |
| Park, S | 1 |
| Kang, S | 1 |
| Kim, DS | 1 |
| Shin, BK | 1 |
| Moon, NR | 1 |
| Daily, JW | 1 |
| Wong, CH | 1 |
| Bozinovski, S | 1 |
| Hertzog, PJ | 1 |
| Hickey, MJ | 1 |
| Crack, PJ | 1 |
| Seo, JY | 1 |
| Lee, CH | 1 |
| Cho, JH | 1 |
| Choi, JH | 1 |
| Yoo, KY | 1 |
| Kim, DW | 1 |
| Park, OK | 1 |
| Li, H | 1 |
| Choi, SY | 1 |
| Bordet, R | 1 |
| Ouk, T | 1 |
| Onténiente, B | 1 |
| Charriaut-Marlangue, C | 1 |
| Heurteaux, C | 1 |
| Koizumi, H | 1 |
| Fujisawa, H | 1 |
| Suehiro, E | 1 |
| Shirao, S | 1 |
| Suzuki, M | 1 |
| Imai, H | 2 |
| Graham, DI | 4 |
| Masayasu, H | 5 |
| Macrae, IM | 4 |
| Salom, JB | 1 |
| Pérez-Asensio, FJ | 1 |
| Burguete, MC | 1 |
| Marín, N | 1 |
| Pitarch, C | 1 |
| Torregrosa, G | 1 |
| Romero, FJ | 1 |
| Alborch, E | 1 |
| Green, AR | 1 |
| Ashwood, T | 1 |
| Shi, H | 1 |
| Liu, S | 1 |
| Miyake, M | 1 |
| Liu, KJ | 1 |
| Dawson, DA | 1 |
| Takasago, T | 1 |
| Peters, EE | 1 |
| Yamaguchi, T | 1 |
| Sano, K | 2 |
| Takakura, K | 3 |
| Saito, I | 2 |
| Shinohara, Y | 1 |
| Asano, T | 3 |
| Yasuhara, H | 1 |
| Abe, H | 1 |
| Yoshimoto, T | 1 |
| Kikuchi, H | 1 |
| Ohta, T | 1 |
| Ishibashi, S | 1 |
| Bastianetto, S | 1 |
| Zheng, WH | 1 |
| Quirion, R | 1 |
| Gladilin, S | 1 |
| Bidmon, HJ | 1 |
| Divanach, A | 1 |
| Arteel, GE | 1 |
| Witte, OW | 1 |
| Zilles, K | 1 |
| Sies, H | 2 |
| Parnham, M | 1 |
| Dewar, D | 1 |
| Rossato, JI | 1 |
| Zeni, G | 1 |
| Mello, CF | 1 |
| Rubin, MA | 1 |
| Rocha, JB | 1 |
| Johshita, H | 1 |
| Sasaki, T | 1 |
| Matsui, T | 1 |
| Hanamura, T | 1 |
3 reviews available for ebselen and Cerebral Ischemia
| Article | Year |
|---|---|
[Cerebral ischaemia: tomorrow's therapeutic tracks].
Topics: Apoptosis; Astrocytes; Azoles; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Endothe | 2009 |
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica | 2005 |
Ebselen: prospective therapy for cerebral ischaemia.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Dogs; Humans; Isoindoles; Organoselenium Compounds; R | 2000 |
2 trials available for ebselen and Cerebral Ischemia
| Article | Year |
|---|---|
Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 1998 |
Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Antioxidants; Azoles; Brain Ischemia; Double-Blind Method; Female; Humans; Incidence; Intracra | 1998 |
17 other studies available for ebselen and Cerebral Ischemia
| Article | Year |
|---|---|
Design and biological evaluation of novel antioxidants containing N-t-Butyl-N-hydroxylaminophenyl moieties.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Cell Death; Cell Survival; Drug Design; Electron Spin | 2003 |
Ebselen alleviates white matter lesions and improves cognitive deficits by attenuating oxidative stress via Keap1/Nrf2 pathway in chronic cerebral hypoperfusion mice.
Topics: Animals; Brain Ischemia; Carotid Stenosis; Cognition; Cognitive Dysfunction; Demyelinating Diseases; | 2023 |
Effects of ebselen on ischemia/reperfusion injury in rat brain.
Topics: Animals; Azoles; Brain; Brain Ischemia; Catalase; Disease Models, Animal; Glutathione Peroxidase; Is | 2014 |
Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Brain Ischemia; Cell Survival; Cytokines; | 2014 |
Absence of glutathione peroxidase-1 exacerbates cerebral ischemia-reperfusion injury by reducing post-ischemic microvascular perfusion.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation; Disea | 2008 |
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes.
Topics: 4-Aminobutyrate Transaminase; Animals; Azoles; Blotting, Western; Brain Ischemia; Cell Death; Gerbil | 2009 |
Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide.
Topics: Animals; Azoles; Brain Ischemia; CA1 Region, Hippocampal; Cerebrovascular Circulation; Disease Model | 2011 |
Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Immunohistochemistry; Isoindoles; Male; Organoseleniu | 2003 |
Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.
Topics: Administration, Oral; Animals; Azoles; Body Weight; Brain; Brain Chemistry; Brain Ischemia; Drug Adm | 2004 |
Ebselen induced C6 glioma cell death in oxygen and glucose deprivation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Azoles; Brain Ischemia; Cell Death; | 2006 |
The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Topics: Animals; Antioxidants; Azoles; Blood Pressure; Brain Ischemia; Caudate Nucleus; Cerebral Cortex; Dis | 1995 |
Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Azoles; Brain Ischemia; Disease Mode | 1997 |
The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C.
Topics: Alkaloids; Alzheimer Disease; Animals; Antioxidants; Azoles; Benzophenanthridines; Brain Ischemia; C | 2000 |
Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia.
Topics: Animals; Antioxidants; Azoles; Brain; Brain Ischemia; Heme Oxygenase (Decyclizing); Heme Oxygenase-1 | 2000 |
Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia.
Topics: Animals; Antioxidants; Axons; Azoles; Brain; Brain Ischemia; Disease Models, Animal; DNA Damage; Inf | 2001 |
Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat.
Topics: Animals; Azoles; Behavior, Animal; Brain Ischemia; Drug Interactions; Grooming; Isoindoles; Lipid Pe | 2002 |
Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats.
Topics: Animals; Antioxidants; Azoles; Brain Edema; Brain Ischemia; Cats; Cerebrovascular Circulation; Isoin | 1990 |